Bedrijfsoverzicht
Lantern Pharma Inc. is a biotechnology entity dedicated to the discovery and development of oncology drugs, with a specific operational focus on the Indian market for its therapeutic candidates. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized developer of novel treatments for serious conditions such as non-small cell lung cancer adenocarcinoma. As of the latest data, Lantern Pharma Inc. maintains a market capitalization of $22.17M and employs 16 individuals to execute its research and development initiatives. The combination of a relatively small market cap and the absence of reported annual revenue indicates that the company is currently in a pre-commercial or early-stage development phase, where value is derived from intellectual property and clinical trial progress rather than current sales volumes.
Financiële gezondheid
The financial statements for Lantern Pharma Inc. show a Net Income (TTM) of $-17,119,438 and an EBITDA of $-17,961,214, while the Revenue (TTM) is not available, which highlights that the company has not yet generated sufficient commercial sales to offset its substantial operating expenses. The gap between the reported negative net income and the negative EBITDA reveals a significant cost structure burden, primarily driven by interest expenses and other non-operating costs that are typical for early-stage biotechs lacking revenue streams. Free Cash Flow stands at $-9,179,892, indicating that the company is consuming cash reserves to fund its operations and clinical trials, thereby limiting its current financial flexibility for external expansion or large-scale acquisitions. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a standard presentation for development-stage companies where costs are recognized before any revenue is realized, rendering traditional profitability analysis inapplicable at this stage. The company holds $10.12M in cash against total debt of $78,539, resulting in a Debt to Equity ratio of 1.20, which suggests a leveraged balance sheet where liabilities exceed equity, yet the absolute debt amount remains low relative to available liquidity. The Current Ratio is reported at 2.40, indicating that the company possesses 2.40 dollars of current assets for every dollar of current liabilities, suggesting a strong position regarding short-term liquidity obligations. Furthermore, the Return on Equity is -123.5% and the Return on Assets is -61.4%, metrics that reflect the dilutive impact of losses on shareholder value and the inefficiency of asset utilization when measured against negative earnings, common characteristics for firms investing heavily in long-term R&D.
Waarderingsbeoordeling
Valuation metrics for Lantern Pharma Inc. present a challenging picture due to the lack of profitability, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.98, implying that the market is pricing in future earnings expectations that are currently negative or undefined. The Price to Book ratio stands at 3.39, suggesting that the market values the company at 3.39 times its book value, a premium that investors likely attribute to the potential value of its drug pipeline rather than tangible assets. Price to Sales is N/A and the EV/EBITDA is -0.68, which are alternative valuation multiples that fail to provide a standard comparison benchmark for profitable peers but instead highlight the speculative nature of investing in a company with negative earnings and no sales history. The stock's recent trading range is defined by a 52-Week High of $5.74 and a 52-Week Low of $1.11, meaning the current valuation sits somewhere within this wide band, reflecting high volatility typical of small-cap biotechnology firms. The Beta value is 1.75, which indicates that the stock price is expected to be 75% more volatile than the broader market, exposing investors to significantly higher price swings during periods of market turbulence.
Growth & Income
Growth rates for Lantern Pharma Inc. are recorded as N/A for both Revenue Growth (YoY) and Earnings Growth (YoY) due to the absence of positive revenue and earnings figures in the trailing twelve months. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue because the company has not yet achieved commercialization of its oncology drugs, such as LP-300 or LP-184, which are currently in clinical trials. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that all available cash flows and retained earnings are directed back into research, development, and clinical trial expenses rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology companies in the discovery and development phases, where capital must be preserved to advance candidates through Phase 1 and Phase 2 trials before any income generation can occur. The overall growth and income profile is characterized by a total lack of current financial returns and growth metrics, relying entirely on the successful execution of its clinical pipeline to transition into a revenue-generating business model in the future.